$9.53
-0.27-2.76%
Last update: 2:35 PM
15 minutes delayed
Comments
Loading...
Travere Therapeutics
TVTXNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Travere Therapeutics (NASDAQ:TVTX) Stock, Analyst Ratings, Price Targets, Forecasts
Travere Therapeutics Inc has a consensus price target of $20.73 based on the ratings of 17 analysts. The high is $46 issued by Piper Sandler on February 21, 2023. The low is $9 issued by Wells Fargo on February 16, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Canaccord Genuity, and HC Wainwright & Co. on May 7, 2024, May 7, 2024, and April 24, 2024, respectively. With an average price target of $18.67 between HC Wainwright & Co., Canaccord Genuity, and HC Wainwright & Co., there's an implied 90.48% upside for Travere Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Canaccord Genuity
Wedbush
Wells Fargo
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Travere Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/07/2024 | Buy Now | 93.88% | HC Wainwright & Co. | Ed Arce | → $19 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | 83.67% | Canaccord Genuity | Edward Nash | $15 → $18 | Maintains | Buy | Get Alert |
| 04/24/2024 | Buy Now | 93.88% | HC Wainwright & Co. | Ed Arce | $17 → $19 | Maintains | Buy | Get Alert |
| 04/17/2024 | Buy Now | 32.65% | Wedbush | Laura Chico | → $13 | Reiterates | Outperform → Outperform | Get Alert |
| 03/27/2024 | Buy Now | — | Guggenheim | Vamil Divan | — | Downgrade | Buy → Neutral | Get Alert |
| 03/13/2024 | Buy Now | 73.47% | HC Wainwright & Co. | Ed Arce | $17 → $17 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | -8.16% | Wells Fargo | Mohit Bansal | $8 → $9 | Maintains | Equal-Weight | Get Alert |
| 02/16/2024 | Buy Now | 32.65% | Wedbush | Laura Chico | → $13 | Reiterates | Outperform → Outperform | Get Alert |
| 01/18/2024 | Buy Now | 12.24% | Piper Sandler | Nicole Gabreski | $10 → $11 | Maintains | Neutral | Get Alert |
| 12/18/2023 | Buy Now | 2.04% | Stifel | Alex Thompson | $8 → $10 | Maintains | Hold | Get Alert |
| 12/15/2023 | Buy Now | 104.08% | HC Wainwright & Co. | Ed Arce | $18 → $20 | Maintains | Buy | Get Alert |
| 12/05/2023 | Buy Now | 2.04% | Citigroup | Carly Kenselaar | $7 → $10 | Upgrade | Neutral → Buy | Get Alert |
| 12/05/2023 | Buy Now | 83.67% | HC Wainwright & Co. | Ed Arce | → $18 | Reiterates | Buy → Buy | Get Alert |
| 11/20/2023 | Buy Now | -28.57% | Citigroup | Carly Kenselaar | → $7 | Initiates | → Neutral | Get Alert |
| 10/25/2023 | Buy Now | 2.04% | Piper Sandler | Nicole Gabreski | $19 → $10 | Maintains | Neutral | Get Alert |
| 09/29/2023 | Buy Now | 22.45% | Wedbush | Laura Chico | → $12 | Reiterates | Outperform → Outperform | Get Alert |
| 09/22/2023 | Buy Now | 22.45% | Barclays | Carter Gould | $31 → $12 | Maintains | Overweight | Get Alert |
| 09/22/2023 | Buy Now | 175.51% | B of A Securities | Greg Harrison | $41 → $27 | Maintains | Buy | Get Alert |
| 09/22/2023 | Buy Now | 83.67% | Guggenheim | Vamil Divan | $25 → $18 | Maintains | Buy | Get Alert |
| 09/22/2023 | Buy Now | 42.86% | Evercore ISI Group | Liisa Bayko | $30 → $14 | Maintains | Outperform | Get Alert |
| 09/22/2023 | Buy Now | 83.67% | HC Wainwright & Co. | Ed Arce | $32 → $18 | Maintains | Buy | Get Alert |
| 09/22/2023 | Buy Now | -18.37% | Wells Fargo | Mohit Bansal | $24 → $8 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 09/21/2023 | Buy Now | — | William Blair | Tim Lugo | — | Downgrade | Outperform → Market Perform | Get Alert |
| 09/19/2023 | Buy Now | 206.12% | Evercore ISI Group | Liisa Bayko | $30 → $30 | Maintains | Outperform | Get Alert |
| 09/06/2023 | Buy Now | 206.12% | Evercore ISI Group | Liisa Bayko | → $30 | Reinstates | Outperform → Outperform | Get Alert |
| 08/18/2023 | Buy Now | 93.88% | Piper Sandler | Nicole Gabreski | $22 → $19 | Maintains | Neutral | Get Alert |
| 08/07/2023 | Buy Now | 226.53% | HC Wainwright & Co. | Ed Arce | $35 → $32 | Reiterates | Buy → Buy | Get Alert |
| 07/21/2023 | Buy Now | 165.31% | JP Morgan | Anupam Rama | → $26 | Initiates | → Overweight | Get Alert |
| 07/18/2023 | Buy Now | 257.14% | Canaccord Genuity | Edward Nash | $37 → $35 | Maintains | Buy | Get Alert |
| 06/21/2023 | Buy Now | 134.69% | Wedbush | Laura Chico | → $23 | Reiterates | Outperform → Outperform | Get Alert |
| 06/07/2023 | Buy Now | 124.49% | Piper Sandler | Nicole Gabreski | → $22 | Assumes | → Neutral | Get Alert |
| 06/01/2023 | Buy Now | 257.14% | HC Wainwright & Co. | Ed Arce | $22 → $35 | Reiterates | → Buy | Get Alert |
| 05/22/2023 | Buy Now | 206.12% | TD Cowen | Tyler Van Buren | → $30 | Initiates | → Outperform | Get Alert |
| 05/02/2023 | Buy Now | 124.49% | HC Wainwright & Co. | Ed Arce | $40 → $22 | Maintains | Buy | Get Alert |
| 05/02/2023 | Buy Now | 297.96% | B of A Securities | Greg Harrison | $52 → $39 | Maintains | Buy | Get Alert |
| 05/02/2023 | Buy Now | 165.31% | Evercore ISI Group | Liisa Bayko | $36 → $26 | Maintains | Outperform | Get Alert |
| 05/02/2023 | Buy Now | 144.9% | Wells Fargo | Mohit Bansal | $28 → $24 | Maintains | Overweight | Get Alert |
| 05/02/2023 | Buy Now | 134.69% | Guggenheim | Vamil Divan | $40 → $23 | Maintains | Buy | Get Alert |
| 04/17/2023 | Buy Now | 195.92% | Wedbush | Laura Chico | $30 → $29 | Maintains | Outperform | Get Alert |
| 03/01/2023 | Buy Now | 277.55% | Guggenheim | Vamil Divan | → $37 | Initiates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | 328.57% | Canaccord Genuity | Edward Nash | $44 → $42 | Maintains | Buy | Get Alert |
| 02/24/2023 | Buy Now | 308.16% | HC Wainwright & Co. | Ed Arce | → $40 | Reiterates | → Buy | Get Alert |
| 02/22/2023 | Buy Now | 348.98% | Canaccord Genuity | Edward Nash | $40 → $44 | Maintains | Buy | Get Alert |
| 02/21/2023 | Buy Now | 369.39% | Piper Sandler | Do Kim | $42 → $46 | Maintains | Overweight | Get Alert |
| 02/21/2023 | Buy Now | 206.12% | Wedbush | Laura Chico | → $30 | Upgrade | Neutral → Outperform | Get Alert |
| 02/21/2023 | Buy Now | 216.33% | Barclays | Carter Gould | $37 → $31 | Maintains | Overweight | Get Alert |
| 02/21/2023 | Buy Now | 308.16% | HC Wainwright & Co. | Ed Arce | $36 → $40 | Reiterates | → Buy | Get Alert |
| 02/17/2023 | Buy Now | 267.35% | HC Wainwright & Co. | Ed Arce | → $36 | Reiterates | → Buy | Get Alert |
| 01/30/2023 | Buy Now | 308.16% | Canaccord Genuity | Edward Nash | $33 → $40 | Maintains | Buy | Get Alert |
| 01/11/2023 | Buy Now | 328.57% | Piper Sandler | Do Kim | $38 → $42 | Maintains | Overweight | Get Alert |
| 12/14/2022 | Buy Now | 124.49% | Stifel | Alex Thompson | → $22 | Initiates | → Hold | Get Alert |
| 12/05/2022 | Buy Now | 185.71% | Wells Fargo | — | → $28 | Initiates | → Overweight | Get Alert |
| 10/20/2022 | Buy Now | 287.76% | SVB Leerink | Joseph Schwartz | $45 → $38 | Maintains | Outperform | Get Alert |
| 10/17/2022 | Buy Now | 267.35% | HC Wainwright & Co. | Ed Arce | $42 → $36 | Maintains | Buy | Get Alert |
| 10/14/2022 | Buy Now | 287.76% | Piper Sandler | Do Kim | $39 → $38 | Maintains | Overweight | Get Alert |
| 08/08/2022 | Buy Now | 328.57% | HC Wainwright & Co. | Ed Arce | $46 → $42 | Maintains | Buy | Get Alert |
| 08/05/2022 | Buy Now | 359.18% | SVB Leerink | Joseph Schwartz | $42 → $45 | Maintains | Outperform | Get Alert |
| 07/26/2022 | Buy Now | 318.37% | Piper Sandler | Do Kim | $40 → $41 | Maintains | Overweight | Get Alert |
| 07/14/2022 | Buy Now | 328.57% | Canaccord Genuity | Edward Nash | → $42 | Assumes | → Buy | Get Alert |
| 05/17/2022 | Buy Now | 369.39% | HC Wainwright & Co. | Ed Arce | $45 → $46 | Maintains | Buy | Get Alert |
| 05/06/2022 | Buy Now | 308.16% | Piper Sandler | Do Kim | $42 → $40 | Maintains | Overweight | Get Alert |
| 03/31/2022 | Buy Now | 328.57% | Piper Sandler | Do Kim | → $42 | Initiates | → Overweight | Get Alert |
| 02/28/2022 | Buy Now | 359.18% | HC Wainwright & Co. | Ed Arce | → $45 | Initiates | → Buy | Get Alert |
| 12/16/2021 | Buy Now | 308.16% | Barclays | Carter Gould | — | Maintains | Overweight | Get Alert |
| 12/16/2021 | Buy Now | 328.57% | SVB Leerink | Joseph Schwartz | — | Maintains | Outperform | Get Alert |
| 08/17/2021 | Buy Now | 277.55% | SVB Leerink | Joseph Schwartz | — | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Travere Therapeutics (TVTX) stock?
The latest price target for Travere Therapeutics (NASDAQ:TVTX) was reported by HC Wainwright & Co. on May 7, 2024. The analyst firm set a price target for $19.00 expecting TVTX to rise to within 12 months (a possible 99.37% upside). 27 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Travere Therapeutics (TVTX)?
The latest analyst rating for Travere Therapeutics (NASDAQ:TVTX) was provided by HC Wainwright & Co., and Travere Therapeutics reiterated their buy rating.
When was the last upgrade for Travere Therapeutics (TVTX)?
The last upgrade for Travere Therapeutics Inc happened on December 5, 2023 when Citigroup raised their price target to $10. Citigroup previously had a neutral for Travere Therapeutics Inc.
When was the last downgrade for Travere Therapeutics (TVTX)?
The last downgrade for Travere Therapeutics Inc happened on March 27, 2024 when Guggenheim changed their price target from N/A to N/A for Travere Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Travere Therapeutics (TVTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Travere Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Travere Therapeutics was filed on May 7, 2024 so you should expect the next rating to be made available sometime around May 7, 2025.
Is the Analyst Rating Travere Therapeutics (TVTX) correct?
While ratings are subjective and will change, the latest Travere Therapeutics (TVTX) rating was a reiterated with a price target of $19.00 to $19.00. The current price Travere Therapeutics (TVTX) is trading at is $9.53, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.